Amylyx Pharmaceuticals, Inc.
http://amylyx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amylyx Pharmaceuticals, Inc.
Real-World Data Or Studies Of Competitor Drugs Can Serve As Confirmatory Evidence For US FDA
Draft guidance describes seven types of confirmatory evidence that can be used with one adequate and well-controlled clinical study to demonstrate substantial evidence of effectiveness, including evidence from expanded access, real-world data, and studies of other drugs in the same class.
Impasse At US FDA Could Mean Stealth Abandons Barth Syndrome Treatment
In an interview with the Pink Sheet, Stealth’s CEO says she is not confident the company could design a clinical trial in the rare disease that would meet the FDA’s expectations.
Amylyx’s Relyvrio/Albrioza Launch Chugs Along As Firm Gives EU Another Go
The company reported 3,800 ALS patients on drug, a figure that came in slightly below some analyst estimates but which suggested discontinuation rates consistent with the pivotal trial.
Regulators Still To Get To Grips With Neurodegenerative Outcome Measures
Outcomes measures in the neurodegenerative disease space are not yet well understood by regulators, according to Amylyx, which recently received a negative opinion from the EMA for its amyotrophic lateral sclerosis drug, Albrioza.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice